文献速递心境障碍

跨健康人群、双相障碍及锂盐治疗的风险决策适应神经特征

Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment.
PubMed 文献 · Mol Psychiatry · 2025-01-29

研究纳入心境障碍问卷(MDQ)高评分疑似双相障碍高危志愿者40例与低评分者37例,以及双相障碍患者随机双盲接受六周锂盐(19例)或安慰剂(16例)治疗。结果显示,获胜后风险规避(结果历史效应)随双相障碍风险升高和确诊而减弱,锂盐未逆转该任务模式,也未改变躁狂或抑郁症状,但改变了背外侧前额叶皮层的奖赏加工。

要点

  • 获胜后风险规避在低MDQ组明显,高MDQ组减弱,双相障碍患者最不明显。
  • 决策时内侧额极激活与结果历史效应相关,高MDQ组较低MDQ组该激活降低。
  • 锂盐未逆转双相障碍的任务模式,也未改变躁狂或抑郁症状,但改变了背外侧前额叶奖赏加工。

核心结论

  • 对奖赏结果的风险决策调节随双相障碍风险和确诊双相障碍而减弱,结果为奖赏如何促发双相障碍风险相关行为升级及心境稳定治疗机制提供模型。

研究设计与样本

  • 招募MDQ高评分(n=40)疑似双相障碍高危志愿者与低评分(n=37)者,另招募确诊双相障碍患者,经两周基线期后随机双盲分配至六周锂盐(n=19)或安慰剂(n=16),其中功能磁共振成像(fMRI)分析n=22。
  • 参与者在50天(MDQ研究)或42天(双相障碍研究)内每日完成心境评分,并完成风险决策任务与fMRI。
  • 任务测量风险承担对既往结果的适应,即前次获胜相对失败后风险规避增加,称为「结果历史」。

主要发现

  • 低MDQ组获胜后风险规避,高MDQ组该效应较不明显,双相障碍患者最不明显。
  • fMRI中「结果历史」与决策时内侧额极激活相关,高MDQ组较低MDQ组该激活降低。
  • 锂盐未逆转双相障碍在任务中的模式,也未改变躁狂或抑郁临床症状,但改变了背外侧前额叶皮层的奖赏加工。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cognitive and neural mechanisms underlying bipolar disorder (BD) and its treatment are still poorly understood. Here we examined the role of adaptations in risk-taking using a reward-guided decision-making task. We recruited volunteers with high (n = 40) scores on the Mood Disorder Questionnaire, MDQ, suspected of high risk for bipolar disorder and those with low-risk scores (n = 37). We also recruited patients diagnosed with BD who were assigned (randomized, double-blind) to six weeks of lithium (n = 19) or placebo (n = 16) after a two-week baseline period (n = 22 for FMRI). Participants completed mood ratings daily over 50 (MDQ study) or 42 (BD study) days, as well as a risky decision-making task and functional magnetic resonance imaging. The task measured adaptation of risk taking to past outcomes (increased risk aversion after a previous win vs. loss, 'outcome history'). While the low MDQ group was risk averse after a win, this was less evident in the high MDQ group and least so in the patients with BD. During fMRI, 'outcome history' was linked to medial frontal pole activation at the time of the decision and this activation was reduced in the high risk MDQ vs. the low risk MDQ group. While lithium did not reverse the pattern of BD in the task, nor changed clinical symptoms of mania or depression, it changed reward processing in the dorsolateral prefrontal cortex. Participants' modulation of risk-taking in response to reward outcomes was reduced as a function of risk for BD and diagnosed BD. These results provide a model for how reward may prime escalation of risk-related behaviours in bipolar disorder and how mood stabilising treatments may work.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Scholl J, Panchal P, Nelissen N, et al. Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment. Mol Psychiatry. 2025. PMID: 39880901. doi:10.1038/s41380-025-02900-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。